Search results
Showing 1 to 7 of 7 results for reslizumab
Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.
Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults.
Benralizumab for treating severe eosinophilic asthma (TA565)
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.
Dupilumab for treating severe asthma with type 2 inflammation (TA751)
Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.
Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.
We are listening to your views on this Technology appraisal guidance. Comments close 17 July 2024.
In development [GID-TA11355] Expected publication date: 12 February 2025